WO2001040463A1 - Nouvelle proteine endoplasmique a reticulum localise, remedes contenant cette proteine destines a des maladies associees a une anomalie glycoproteique, adn codant cette proteine et remedes genetiques contenant cet adn destines au traitement de maladies associees a une anomalie glycoproteique - Google Patents
Nouvelle proteine endoplasmique a reticulum localise, remedes contenant cette proteine destines a des maladies associees a une anomalie glycoproteique, adn codant cette proteine et remedes genetiques contenant cet adn destines au traitement de maladies associees a une anomalie glycoproteique Download PDFInfo
- Publication number
- WO2001040463A1 WO2001040463A1 PCT/JP2000/008529 JP0008529W WO0140463A1 WO 2001040463 A1 WO2001040463 A1 WO 2001040463A1 JP 0008529 W JP0008529 W JP 0008529W WO 0140463 A1 WO0140463 A1 WO 0140463A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- glycoprotein
- dna
- gene
- abnormality
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- calreticulin is also a Ca 2+ -binding soluble protein present in the ER, and has a molecular weight of 46 kDa (400 amino acids) and a ER localization signal (KDEL) at the C-terminus. It is a homolog. See Michalak, M. et al., Exp. Ce 11 Res., 197, 91-99, 1991.
- the ELP of the present invention and the DNA of the present invention can be used for mutated sugars such as cystic fibrosis, juvenile emphysema, teasach's disease, congenital sucrose isomaltase deficiency, familial hypercholesterolemia, etc. It may be useful in the treatment of glycoprotein disorders due to proteins staying in the ER for prolonged periods without deviating from calnexin.
- oligonucleotide refers to oligonucleotides and analogs thereof formed from naturally occurring bases and sugar moieties linked by native phosphodiester bonds.
- first group included by this term is a naturally occurring species, or a naturally occurring subunit or a homologue thereof.
- the subunit refers to a combination of base monosaccharides bonded to an adjacent subunit by a phosphodiester bond or another bond.
- a second group of oligonucleotides are analogs thereof, which function similarly to the oligonucleotides, but which have residues with non-naturally occurring portions.
- Example 2 Isolation, purification and identification of ELP protein
- a cell lysate was extracted from human cancer clothing 549 used as a source of the cDNA library at the time of the above-mentioned cDNA cloning according to a conventional method. After this was roughly purified by gel filtration, it was further purified by electrophoresis in ⁇ .53 ⁇ 4 SDS-PAGE. Thereafter, the amino acid sequence was transferred to a PVDF membrane, and the amino acid sequence of the ELP blotted on the filter was determined using a gas phase protein sensor as it was. This result was completely consistent with the amino acid sequence deduced from the cDNA sequence. The sequence determined in this manner is shown in SEQ ID NO: 1 in the sequence listing.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU15570/01A AU1557001A (en) | 1999-12-03 | 2000-12-01 | Novel endoplasmic reticulum-localized protein, remedies containing the same for diseases associated with glycoprotein abnormality, dna encoding this protein andgene remedies containing the same for treating diseases associated with glycopr otein abnormality |
EP00978059A EP1251171A4 (en) | 1999-12-03 | 2000-12-01 | NOVEL ENDOPLASMIC PROTEIN WITH LOCALIZED RETICULUM, REMEDIES CONTAINING THIS PROTEIN FOR DISEASES ASSOCIATED WITH GLYCOPROTEIC ANOMALY, DNA ENCODING SAME, AND GENETIC REMEDIES CONTAINING THIS DNA FOR THE TREATMENT OF DISEASES ASSOCIATED WITH GLOBAL ANOMALY |
CA002394016A CA2394016A1 (en) | 1999-12-03 | 2000-12-01 | Novel endoplasmic localization proteins,therapeutic agents for glycoprotein aberration disorders containing same,dna encoding the proteins,and therapeutic agents in gene therapy for glycoprotein aberration disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP34479599A JP2001161363A (ja) | 1999-12-03 | 1999-12-03 | 新規な小胞体局在タンパク質およびそれを含む糖タンパク質異常症治療薬、並びに該タンパク質をコードするdnaおよびそれを含む糖タンパク質異常症治療のための遺伝子治療薬。 |
JP11/344795 | 1999-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001040463A1 true WO2001040463A1 (fr) | 2001-06-07 |
Family
ID=18372056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/008529 WO2001040463A1 (fr) | 1999-12-03 | 2000-12-01 | Nouvelle proteine endoplasmique a reticulum localise, remedes contenant cette proteine destines a des maladies associees a une anomalie glycoproteique, adn codant cette proteine et remedes genetiques contenant cet adn destines au traitement de maladies associees a une anomalie glycoproteique |
Country Status (7)
Country | Link |
---|---|
US (1) | US20030158092A1 (ja) |
EP (1) | EP1251171A4 (ja) |
JP (1) | JP2001161363A (ja) |
CN (1) | CN1413251A (ja) |
AU (1) | AU1557001A (ja) |
CA (1) | CA2394016A1 (ja) |
WO (1) | WO2001040463A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9561262B2 (en) | 2011-06-06 | 2017-02-07 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
AU2015255752B2 (en) * | 2014-05-08 | 2020-07-23 | Immunoforge Co., Ltd. | Methods and compositions for treating Cystic Fibrosis |
US10688156B2 (en) | 2015-02-09 | 2020-06-23 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861244A (en) * | 1992-10-29 | 1999-01-19 | Profile Diagnostic Sciences, Inc. | Genetic sequence assay using DNA triple strand formation |
US5691306A (en) * | 1993-08-26 | 1997-11-25 | National Research Council Of Canada | Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production |
DE69503126T2 (de) * | 1994-05-05 | 1998-11-12 | Beckman Instruments Inc | Repetitive oligonukleotide matrix |
-
1999
- 1999-12-03 JP JP34479599A patent/JP2001161363A/ja active Pending
-
2000
- 2000-12-01 AU AU15570/01A patent/AU1557001A/en not_active Abandoned
- 2000-12-01 CA CA002394016A patent/CA2394016A1/en not_active Abandoned
- 2000-12-01 CN CN00817592A patent/CN1413251A/zh active Pending
- 2000-12-01 EP EP00978059A patent/EP1251171A4/en not_active Withdrawn
- 2000-12-01 US US10/148,587 patent/US20030158092A1/en not_active Abandoned
- 2000-12-01 WO PCT/JP2000/008529 patent/WO2001040463A1/ja not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
IKUO WADA ET AL.: "SSRalpha and associated calnexin are major calcium binding protein of the endoplasmic reticulum membrane", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 29, 1991, pages 19599 - 19610, XP002936555 * |
LARRY W. TJOELKER ET AL.: "Human, mouse and rat calnexin cDNA cloning: Identification of potential calcium binding motifs and gene localization to human chromosome 5", BIOCHEMISTRY, vol. 33, no. 11, 1994, pages 3229 - 3236, XP002936556 * |
See also references of EP1251171A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20030158092A1 (en) | 2003-08-21 |
EP1251171A4 (en) | 2004-05-12 |
CA2394016A1 (en) | 2001-06-07 |
EP1251171A1 (en) | 2002-10-23 |
AU1557001A (en) | 2001-06-12 |
CN1413251A (zh) | 2003-04-23 |
JP2001161363A (ja) | 2001-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7968512B2 (en) | Conjugates that contain the homeodomain of antennapedia | |
JPH09504166A (ja) | リーダー配列なしに細胞質外に輸送される融合ポリペプチドの発現 | |
KR20040015163A (ko) | 폰 빌브란트 인자(vWF)-절단 효소 | |
WO1988005053A1 (en) | Peptide functioning to accelerate activation of protein c with thrombin | |
KR20010012554A (ko) | 항미생물성 펩티드 | |
JPH03224490A (ja) | 神経成長因子を真核生物細胞において発現させるための遺伝子ベクター | |
SK29697A3 (en) | Modified human c3 proteins | |
JP2738428B2 (ja) | トロンビンによるプロテインcの活性化を促進する作用を有するペプチド | |
WO2001040463A1 (fr) | Nouvelle proteine endoplasmique a reticulum localise, remedes contenant cette proteine destines a des maladies associees a une anomalie glycoproteique, adn codant cette proteine et remedes genetiques contenant cet adn destines au traitement de maladies associees a une anomalie glycoproteique | |
EP0668911A1 (en) | Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor | |
KR101651330B1 (ko) | 세포투과성이 우수한 tat-a20 융합단백질의 제조방법 및 이의 용도 | |
JP4544715B2 (ja) | ラットbcl−x遺伝子の改変型cDNAと改変型タンパク質 | |
KR101106262B1 (ko) | 인간 호메오 도메인 유전자 유래의 단백질 도입 도메인 및 이를 이용한 단백질 도입 벡터 | |
Du Bois et al. | Purification and characterization of recombinant forms of TCL-1 and MTCP-1 proteins | |
WO2001023557A1 (fr) | Polypeptides et genes les codant | |
CA2410525A1 (en) | Fas ligand-fused proteins | |
JP2001517064A (ja) | トランスフォーミング増殖因子アルファhi | |
JPH09501825A (ja) | 細菌細胞における組み換え遺伝子の複シストロン性発現 | |
EP1674567A1 (en) | METHOD OF CLEAVING POLYPEPTIDE BY USING OmpT PROTEASE MUTANT | |
WO2002064164A1 (fr) | Regulateurs de l'expression de la proteine gm-csf et/ou defensine dans des cellules epitheliales comprenant un facteur de transcription ets ou un gene le codant | |
JP4549666B2 (ja) | 抗体の製造方法 | |
JP2012509670A (ja) | 血液凝固促進剤としてのヘビ第五因子及び使用方法 | |
KR20000047835A (ko) | 혈액 응고 인자 및 p-셀렉틴의 dna 작제물 | |
KR19990072793A (ko) | Dna서열의유전자수송을위한아데노바이러스전달벡터 | |
JP2023549620A (ja) | 組換え補体タンパク質を産生させる方法、そのベクターおよび治療的使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2394016 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008175926 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000978059 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000978059 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10148587 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000978059 Country of ref document: EP |